Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2INTERVENTIONAL

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

A Phase IIa, Multicenter, Open-label, Single-Arm Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated. The substudy will evaluate the operational feasibility and scientific interpretability of incorporating AO retinal imaging using the EarlySight Cellularis® Discovery device. Participants who have fulfilled the eligibility requirements for the parent study and meet the substudy's eligibility criteria will have the option to participate in the substudy. The EarlySight Cellularis® Discovery device will be used only as an assessment tool and data obtained from this device will not be used to guide clinical care or influence clinical outcomes for participants.

Who May Be Eligible (Plain English)

Who May Qualify: - Ability to undergo a vitreoretinal surgical procedure under monitored anesthesia care - Diagnosis of GA secondary to AMD - Best corrected visual acuity (BCVA) score ≥ 29 letters and ≤ 60 letters in the study eye as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) - Pseudophakic (study eye) Who Should NOT Join This Trial: - Pregnancy or breastfeeding - History of cognitive impairment or dementia - Any type of systemic disease or its treatment, in the opinion of the investigator, including any medical conditions that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the participant to a significant degree or put the participant at special risk Ocular Exclusion Criteria for Study Eye: - Any current or history of ocular disease other than GA that may confound assessment of the macula - History of retinal detachment - History of vitrectomy, glaucoma-filtering surgery, or corneal transplant - Uncontrolled glaucoma or advanced glaucoma - Any cataract surgery or intraocular surgery within 3 months prior to subretinal surgical delivery of OpRegen - History of other ocular or intraocular conditions that contraindicate the use of an investigational drug or may affect interpretation of the study results or may render the participant at high risk for treatment complications - Any existing posterior segment device or implant Substudy: Who May Qualify: \- Participants must meet all of the inclusion criteria described in the parent study GR44251 and have the ability to comply with the substudy protocol Who Should NOT Join This Trial: - Participants who meet any exclusion criteria listed in the parent study GR44251 - Past history of seizures, or epileptic seizures due to any cause except for a single febrile seizure in childhood Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Ability to undergo a vitreoretinal surgical procedure under monitored anesthesia care * Diagnosis of GA secondary to AMD * Best corrected visual acuity (BCVA) score ≥ 29 letters and ≤ 60 letters in the study eye as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) * Pseudophakic (study eye) Exclusion Criteria: * Pregnancy or breastfeeding * History of cognitive impairment or dementia * Any type of systemic disease or its treatment, in the opinion of the investigator, including any medical conditions that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the participant to a significant degree or put the participant at special risk Ocular Exclusion Criteria for Study Eye: * Any current or history of ocular disease other than GA that may confound assessment of the macula * History of retinal detachment * History of vitrectomy, glaucoma-filtering surgery, or corneal transplant * Uncontrolled glaucoma or advanced glaucoma * Any cataract surgery or intraocular surgery within 3 months prior to subretinal surgical delivery of OpRegen * History of other ocular or intraocular conditions that contraindicate the use of an investigational drug or may affect interpretation of the study results or may render the participant at high risk for treatment complications * Any existing posterior segment device or implant Substudy: Inclusion Criteria: \- Participants must meet all of the inclusion criteria described in the parent study GR44251 and have the ability to comply with the substudy protocol Exclusion Criteria: * Participants who meet any exclusion criteria listed in the parent study GR44251 * Past history of seizures, or epileptic seizures due to any cause except for a single febrile seizure in childhood

Treatments Being Tested

BIOLOGICAL

OpRegen

OpRegen dose of up to approximately 200,000 cells will be delivered into the subretinal space.

Locations (17)

Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States
West Coast Retina
San Francisco, California, United States
Retina Vitreous Associates of Florida
St. Petersburg, Florida, United States
The Retina Care Center
Baltimore, Maryland, United States
The Retina Institute
St Louis, Missouri, United States
Sierra Eye Associates
Reno, Nevada, United States
Duke Eye Center
Durham, North Carolina, United States
Cincinnati Eye Institute
Blue Ash, Ohio, United States
Mid Atlantic Retina
Philadelphia, Pennsylvania, United States
Tennessee Retina PC
Nashville, Tennessee, United States
Austin Clinical Research, LLC
Austin, Texas, United States
Retina Consultants of Texas
Bellaire, Texas, United States
Piedmont Eye Center
Lynchburg, Virginia, United States
Spokane Eye Clinical Research;Spokane Eye Surgery Center
Spokane, Washington, United States
Hadassah MC
Jerusalem, Israel
Tel Aviv Sourasky MC
Tel Aviv, Israel